The ASA Biopharmaceutical Section Nonclinical Biostatistics Working Group invites nominations for the 2023 Stan Altan Nonclinical Biostatistics Paper Award.
Throughout his career, Altan has been a champion for the broad range of statistical methods used in nonclinical research. His vision to unify practitioners of nonclinical statistics and emphasize the critical effect of statistics in drug development outside the clinical arena has left its mark on the industry.
Nominated papers must address a relevant topic in nonclinical biostatistics disciplines for the biopharmaceutical industry. The scope of the eligible papers is broad and generally includes anything except topics directly related to clinical trials. This might include topics covered in the book Nonclinical Biostatistics for Pharmaceutical and Biotechnology Industries by Lanju Zhang, Max Kuhn, Ian Peers, and Stan Altan. Topics such as biomarker discovery, pharmacometrics, machine learning, and AI applications that are not directly concerning trial design (phases I–IV) are also welcome.
All eligible papers must have been published—or accepted for publication—in English in refereed journals between January 1, 2016, and March 1, 2023. Send an electronic copy of the paper being nominated to Angel Lu by March 15, 2023.
The best paper award will be presented to the winning author(s) at the 2023 Nonclinical Biostatistics Conference at Rutgers University, New Jersey. Due to COVID-19, the award may be mailed.
Learn more on the BIOP Working Group website.
Leave a Reply